News
For 20 years, the University of Minnesota Center for Drug Design has combined research and scholarship to develop novel drugs for therapeutic applications, such as HIV, other human viral pathogens, neurological diseases, cancers, and much more. CDD research featuring numerous internal and external collaborations and shared within the broad scientific community is typically geared toward developing innovative and marketable technologies to benefit human health.
We celebrated the CDD's 20th Anniversary with a one-day symposium on Tuesday, May 7th, 2024 at McNamara Alumni Center in Minneapolis, MN. Symposium speakers included internationally renowned drug researchers Dr. Dennis Liotta, Dr. Pei-Yong Shi as invited keynote speakers and Dr. Bob Vince as the Founding Director of the CDD.
Researchers from the University of Minnesota Center for Drug Design are getting closer to finding a solution to the problem of White Nose Syndrome affecting bat populations throughout the country.
If there was a way to catch Alzheimer's earlier, to see its onset in the most nascent of stages, medical researchers postulate that would allow patients to access novel treatments earlier than ever before.
Finding a viable treatment for Alzheimer’s disease (AD) continues to frustrate researchers around the world.
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning.
Prof Christine Salomon's lecture 'Tales from the underground: Searching for biocontrol treatments for white nose syndrome in bats' drew a big crowd at University of North Carolina.
Center for Drug Design (College of Pharmacy, University of Minnesota) has signed an agreement to collaborate with medical imaging startup RetiSpec to commercialize the technology for early detection of Alzheimer’s disease.